Isoprenaline (Imuprel)
Isoprenaline
Adcock ingram limited
Every registration of this product has been cancelled.
Registration
- Applicant
- Adcock ingram limited
- Registrations
- 1
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Imuprel injection EACH 1 ml SOLUTION CONTAINS ISOPRENALINE HYDROCHLORIDE A 0,2 mg | Injection | C0774 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Isoprenaline
- when intended for injection.
Consolidated Schedules 06 July 2026, line 6823
S3: Isoprenaline
- when contained in respirator solutions.
Consolidated Schedules 06 July 2026, line 3822
S2: Isoprenaline
- when contained in respirator solutions; (S3) and
- when intended for injection. (S4)
Consolidated Schedules 06 July 2026, lines 2181 to 2185
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
4-[1-Hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol
Drag to rotate. Structure from PubChem CID 3779.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.